|May 2017||Decision whether or not to proceed with the investigation or to close the investigation|
|October 2016 to April 2017||Initial investigation, information gathering, including issuance of formal or information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation|
|October 2016||Investigation opened|
The following changes have been made to the case timetable since it was first published in October 2016:
|Date of change||Reason for change||Change made to timetable|
|20 March 2017||Additional time for evidence gathering and analysis||Date of decision on whether or not to proceed with the investigation extended from April 2017 to May 2017|
|20 January 2017||Additional time for evidence gathering and analysis||Date of decision on whether or not to proceed with the investigation extended from February to April 2017|
On 25 October 2016, the Competition and Markets Authority (CMA) launched an investigation into suspected breaches of competition law by Concordia International RX (UK) Limited. The investigation is under Chapter II of the Competition Act 1998 (CA98) and Article 102 of the Treaty on the Functioning of the European Union (TFEU). The investigation relates to suspected unfair pricing by way of charging excessive prices in the supply of certain pharmaceutical products, including to the National Health Service.
The CMA has not reached a view as to whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to any of the parties under investigation. Not all cases result in the CMA issuing a statement of objections.
Further detail of the CMA’s procedures in CA98 cases is available in our guidance.
Assistant Project Director
Brian Jackson (020 3738 6546, email@example.com)
Ronan Flanagan (020 3738 6142, firstname.lastname@example.org)
Senior Responsible Officer
Geoff Steadman (020 3738 6311, geoff.Steadman@cma.gsi.gov.uk)